Current obesity reports · 2026
Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zenno Anna, Pierce Melinda
Аннотация
PURPOSE OF REVIEW: This review aims to provide a summary of treatment strategies for hypothalamic obesity (HO) and the latest data on pharmacologic interventions for HO.
RECENT FINDINGS: We summarize new consensus diagnostic criteria for acquired HO, non-pharmacologic interventions such as diet and physical activity, medications including the newly FDA approved setmelanotide, metabolic and bariatric surgery, and emerging treatment strategies that address the complex pathophysiology of HO. Hypothalamic obesity is caused by hypothalamic injury that impairs energy balance, metabolism, and satiety and leads to refractory obesity that is resistant to traditional diet and exercise interventions. Despite recent progress, effective long-term management of HO remains challenging, with few controlled trials, significant heterogeneity in patient response, and lack of long-term follow up data. A new medication targeting the melanocortin-4 receptor (MC4R) pathway was recently approved for treatment with additional newer drugs in development [1].
RECENT FINDINGS: We summarize new consensus diagnostic criteria for acquired HO, non-pharmacologic interventions such as diet and physical activity, medications including the newly FDA approved setmelanotide, metabolic and bariatric surgery, and emerging treatment strategies that address the complex pathophysiology of HO. Hypothalamic obesity is caused by hypothalamic injury that impairs energy balance, metabolism, and satiety and leads to refractory obesity that is resistant to traditional diet and exercise interventions. Despite recent progress, effective long-term management of HO remains challenging, with few controlled trials, significant heterogeneity in patient response, and lack of long-term follow up data. A new medication targeting the melanocortin-4 receptor (MC4R) pathway was recently approved for treatment with additional newer drugs in development [1].